# GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

Study · id `cardio:ct-nct04942756` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04942756](<https://clinicaltrials.gov/study/NCT04942756>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04942756

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 118 participants.

## Technical summary

Registry record NCT04942756. Randomized; no masking; primary purpose supportive care. Start 2021-06-30 (actual); primary completion 2022-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 118 participants (planned count; ClinicalTrials.gov record NCT04942756, source copy `cardio:ctgov-nct04942756-2021-07-22`, retrieved 2026-10-26)
- Started: 2021-06-30 (actual) (ClinicalTrials.gov record NCT04942756, source copy `cardio:ctgov-nct04942756-2021-07-22`, retrieved 2026-10-26)
- Primary completion: 2022-06-30 (anticipated) (ClinicalTrials.gov record NCT04942756, source copy `cardio:ctgov-nct04942756-2021-07-22`, retrieved 2026-10-26)
- Completion: 2022-06-30 (anticipated) (ClinicalTrials.gov record NCT04942756, source copy `cardio:ctgov-nct04942756-2021-07-22`, retrieved 2026-10-26)
- Countries: Israel; Italy; Switzerland (ClinicalTrials.gov record NCT04942756, source copy `cardio:ctgov-nct04942756-2021-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04942756-2021-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.
- Condition: Palliative Care
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes
- Condition: Cancer
- Condition: Terminal Cancer
- Condition: Terminal Illness
- Condition: End Stage Cancer
- Condition: Advanced Cancer
- Intervention (Device): Continuous Glucose Monitoring
- Intervention (Device): Standard Care
- Lead sponsor: Antea Foundation
- Lead sponsor class: OTHER
- Collaborator: Abbott Diabetes Care
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Abbott Diabetes Care (`cardio:org-abbott-diabetes-care`)

## Provenance

Content hash: 5a85e533520624f27cb311c30ab9c89d151fc7c2c39a2148cf67054fbd5bcaba
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
